News & Updates
Filter by Specialty:
ACEi-induced cough may occur in one-fourth of primary care prescriptions
Dry cough may affect a quarter of Malay patients initiated on angiotensin-converting enzyme inhibitors (ACEi), according to a new study.
ACEi-induced cough may occur in one-fourth of primary care prescriptions
25 May 2022
OMDI shows potential as first-line treatment for glaucoma in real-world trial
In a retrospective review of real-world data from Japan, omidenepag isopropyl 0.002% ophthalmic solution (OMDI) demonstrated an intraocular pressure (IOP)-lowering effect in eyes with different types of glaucoma, without severe or serious adverse effects.
OMDI shows potential as first-line treatment for glaucoma in real-world trial
24 May 2022
Fewer hospitalizations with omicron vs delta suggest reduced severity of omicron variant
Infection with the omicron variant of SARS-CoV-2 was less likely to result in hospitalization than infection with the delta variant, according to an observational study from Denmark presented at ECCMID 2022 and published in The Lancet.
Fewer hospitalizations with omicron vs delta suggest reduced severity of omicron variant
23 May 2022
Upadacitinib provides robust, long-term control of moderate-to-severe AD
Follow-up data from two replicate ongoing phase III trials – Measure Up 1 and Measure Up 2 – demonstrated favourable longer-term benefit-risk profile of upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis (AD).
Upadacitinib provides robust, long-term control of moderate-to-severe AD
23 May 2022
Which canagliflozin dose is best for T2DM patients with hypertension?
A recent meta-analysis offers new proof of different canagliflozin doses for hypertension management in patients with type 2 diabetes mellitus (T2DM) complicated by hypertension. However, low-density lipoprotein cholesterol (LDL-C) and the risk of urinary tract infection must be observed.